<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">rsp</journal-id><journal-title-group><journal-title xml:lang="ru">Научно-практическая ревматология</journal-title><trans-title-group xml:lang="en"><trans-title>Rheumatology Science and Practice</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1995-4484</issn><issn pub-type="epub">1995-4492</issn><publisher><publisher-name>IMA-PRESS, LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.14412/1995-4484-2019-284-288</article-id><article-id custom-type="elpub" pub-id-type="custom">rsp-2727</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL RESEARCH</subject></subj-group></article-categories><title-group><article-title>Возможности использования калькулятора 10-летней вероятности переломов FRAX® у больных ревматоидным артритом</article-title><trans-title-group xml:lang="en"><trans-title>Possibilities of using a FRAX® risk calculator for 10-year probability of fractures assessment in patients with rheumatoid arthritis</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Никитинская</surname><given-names>О. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Nikitinskaya</surname><given-names>O. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>115522, Москва, Каширское шоссе, 34А.</p></bio><bio xml:lang="en"><p>34A, Kashirskoe Shosse, Moscow, 115522.</p></bio><email xlink:type="simple">nikitinskayaos@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Торопцова</surname><given-names>Н. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Toroptsova</surname><given-names>N. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>115522, Москва, Каширское шоссе, 34А.</p></bio><bio xml:lang="en"><p>34A, Kashirskoe Shosse, Moscow, 115522.</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Насонов</surname><given-names>E. Л.</given-names></name><name name-style="western" xml:lang="en"><surname>Nasonov</surname><given-names>E. L.</given-names></name></name-alternatives><bio xml:lang="ru"><p>115522, Москва, Каширское шоссе, 34А.</p><p>119991, Москва, ул. Трубецкая, 8, стр. 2.</p></bio><bio xml:lang="en"><p>34A, Kashirskoe Shosse, Moscow, 115522.</p><p>8, Trubetskaya Str., Build. 2, Moscow, 119991.</p></bio><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>V.A. Nasonova Research Institute of Rheumatology</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»; ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет)</institution><country>Россия</country></aff><aff xml:lang="en"><institution>V.A. Nasonova Research Institute of Rheumatology</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2019</year></pub-date><pub-date pub-type="epub"><day>09</day><month>07</month><year>2019</year></pub-date><volume>57</volume><issue>3</issue><fpage>284</fpage><lpage>288</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Никитинская О.А., Торопцова Н.В., Насонов E.Л., 2019</copyright-statement><copyright-year>2019</copyright-year><copyright-holder xml:lang="ru">Никитинская О.А., Торопцова Н.В., Насонов E.Л.</copyright-holder><copyright-holder xml:lang="en">Nikitinskaya O.A., Toroptsova N.V., Nasonov E.L.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://rsp.mediar-press.net/rsp/article/view/2727">https://rsp.mediar-press.net/rsp/article/view/2727</self-uri><abstract><p>Ревматоидный артрит (РА) и прием глюкокортикоидов (ГК) являются наиболее частыми причинами вторичного остеопороза (ОП). Раннее выявление среди пациентов с РА лиц с высоким риском остеопоротических переломов позволяет своевременно начать профилактику ОП и его осложнений.</p><p>Цель исследования – оценить диагностические возможности использования калькулятора FRAX® без внесения в алгоритм минеральной плотности кости (МПК) шейки бедренной кости, а также различных порогов терапевтического вмешательства для выделения больных РА, нуждающихся в антиостеопоротической терапии.</p><sec><title>Материал и методы</title><p>Материал и методы. В исследование включены 97 пациентов с РА в возрасте старше 50 лет. Проводилось анкетирование, денситометрическое обследование аксиальных отделов скелета, вычислялся 10-летний риск переломов с помощью калькулятора FRAX® c МПК шейки бедра и без нее. Изучались диагностические характеристики (чувствительность, специфичность, ROC-кривые) различных порогов терапевтического вмешательства (российского и европейского возраст-зависимых; 20% и 10%) для FRAX®.</p></sec><sec><title>Результаты и обсуждение</title><p>Результаты и обсуждение. Возможности российской модели FRAX® как с данными МПК шейки бедра, так и без них выявлять пациентов, нуждающихся в назначении лечения ОП, были очень хорошими (AUC= 0,878±0,036 и AUC=0,872±0,040 соответственно). Показатели двухэнергетической рентгеновской абсорбциометрии поясничного отдела позвоночника также очень хорошо выделяли больных РА, которым показана профилактика ОП и связанных с ним переломов (AUC=0,837±0,063), в то время как значения МПК шейки бедренной кости и всего бедра демонстрировали более низкую точность в определении таких пациентов (AUC=0,587±0,102 и AUC=0,625±0,092 соответственно). Российский возраст-зависимый порог показал 79,7% чувствительность и 63,7% специфичность при оценке алгоритма FRAX® без МПК, для FRAX® c МПК эти показатели составляли 82,2 и 65,2% соответственно. Достоверных различий в выделении лиц, нуждающихся в лечении, с использованием FRAX® без МПК и с МПК выявлено не было (χ2=0,22; p=0,64). Чувствительность и специфичность других порогов терапевтического вмешательства при определении риска перелома с МПК и без нее были следующими: для европейского – 90,4–94,6 и 17,4–21,7%; для 20% – 58,8 и 93,8%, для 10% – 96,5% и 0 соответственно.</p></sec><sec><title>Заключение</title><p>Заключение. У больных РА в возрасте 50 лет и старше для оценки риска перелома может применяться калькулятор FRAX® без внесения в алгоритм данных МПК шейки бедренной кости. Оценка риска перелома должна проводиться с использованием российского возраст-зависимого порога, который в достаточной мере выявляет среди больных РА лиц, нуждающихся в лечении ОП.</p></sec></abstract><trans-abstract xml:lang="en"><p>Rheumatoid arthritis (RA) and glucocorticoid use are the most common causes of secondary osteoporosis (OP). Early detection of individuals at high risk for osteoporotic fractures among RA patients allows timely prevention of OP and its complications.</p><sec><title>Objective</title><p>Objective: to evaluate the diagnostic possibilities of using a FRAX® calculator without introducing femoral neck bone mineral density (BMD) into the algorithm, as well as different therapeutic intervention thresholds to identify RA patients who need anti-osteoporotic therapy.</p></sec><sec><title>Subjects and methods</title><p>Subjects and methods. The investigation enrolled 97 RA patients aged over 50 years. A questionnaire survey and axial skeletal densitometry were made; the 10-year fracture risk was calculated using the FRAX® calculator with and without femoral neck BMD. The diagnostic characteristics (sensitivity, specificity, ROC-curves) of different therapeutic intervention thresholds (Russian and European age-dependent intervention thresholds; 20% and 10%) for FRAX) were studied.</p></sec><sec><title>Results and discussion</title><p>Results and discussion. The capabilities of the Russian FRAX® model with and without femoral neck BMD to identify patients requiring treatment for OP were very good (AUC=0.878±0.036 and AUC=0.872±0.040, respectively). Lumbar spine dual-energy X-ray absorptiometry also identified very well RA patients who should undergo prophylaxis against OP and related fractures (AUC=0.837±0.063), while femoral neck and whole hip BMD values showed lower accuracy in detecting these patients (AUC=0.587±0.102 and AUC=0.625±0.092, respectively). The Russian age-dependent threshold showed 79.7% sensitivity and 63.7% specificity in evaluating the FRAX® algorithm without BMD; these figures for FRAX® with BMD were 82.2 and 65.2%, respectively. The use of FRAX® without and with BMD revealed no significant differences in the identification of persons in need of treatment (χ2=0.22; p=0.64). The sensitivity and specificity of other therapeutic intervention thresholds in determining the fracture risk with and without BMD were as follows: 90.4-94.6 and 17.4-21.7% for the European threshold; 58.8 and 93.8% for 20%, and 96.5% and 0 for 10%, respectively.</p></sec><sec><title>Conclusion</title><p>Conclusion. The FRAX® calculator can be used to assess a fracture risk without entering the femoral neck BMD data into the algorithm for RA patients aged 50 years and older. Fracture risk should be assessed using the Russian agedependent threshold that adequately identifies those who need OP treatment among RA patients.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>остеопороз</kwd><kwd>ревматоидный артрит</kwd><kwd>10-летний риск переломов</kwd><kwd>FRAX®</kwd><kwd>минеральная плотность кости</kwd><kwd>порог терапевтического вмешательства</kwd></kwd-group><kwd-group xml:lang="en"><kwd>osteoporosis</kwd><kwd>rheumatoid arthritis</kwd><kwd>10-year fracture risk</kwd><kwd>FRAX®</kwd><kwd>bone mineral density</kwd><kwd>therapeutic intervention threshold</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Silvermann S, Curtis J, Saag K, et al. International management of bone health in glucocorticoid-exposed individuals in the observational GLOW study. Osteoporos Int. 2015;26:419-20. doi: 10.1007/s00198-014-2883-2</mixed-citation><mixed-citation xml:lang="en">Silvermann S, Curtis J, Saag K, et al. International management of bone health in glucocorticoid-exposed individuals in the observational GLOW study. Osteoporos Int. 2015;26:419-20. doi: 10.1007/s00198-014-2883-2</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Roux C. Osteoporosis in inflammatory joint diseases. Osteoporos Int. 2011;22:421-33. doi: 10.1007/s00198-010-1319-x</mixed-citation><mixed-citation xml:lang="en">Roux C. Osteoporosis in inflammatory joint diseases. Osteoporos Int. 2011;22:421-33. doi: 10.1007/s00198-010-1319-x</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Van Staa TP, Geusens P, Bilsma JWJ, et al. Clinical assessment of long-term risk of fracture in patients with rheumatoid arthritis. Arthritis Rheum. 2006;54(10):3104-12.</mixed-citation><mixed-citation xml:lang="en">Van Staa TP, Geusens P, Bilsma JWJ, et al. Clinical assessment of long-term risk of fracture in patients with rheumatoid arthritis. Arthritis Rheum. 2006;54(10):3104-12.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Haugeberg G, Uhlig T, Falch JA, et al. Bone mineral density and frequency of osteoporosis in female patients with rheumatoid arthritis. Arthritis Rheum. 2000;42(3):522-30. doi: 10.1002/1529-0131(200003)43:3&lt;522::AID-ANR7&gt;3.0.CO;2-Y</mixed-citation><mixed-citation xml:lang="en">Haugeberg G, Uhlig T, Falch JA, et al. Bone mineral density and frequency of osteoporosis in female patients with rheumatoid arthritis. Arthritis Rheum. 2000;42(3):522-30. doi: 10.1002/1529-0131(200003)43:3&lt;522::AID-ANR7&gt;3.0.CO;2-Y</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Smulders E, Schreven C, Weerdesteyn, et al. Fall incidence and fall risk factors in people with rheumatoid arthritis. Ann Rheum Dis. 2009;68:1795-6. doi: 10.1136/ard.2009.109009</mixed-citation><mixed-citation xml:lang="en">Smulders E, Schreven C, Weerdesteyn, et al. Fall incidence and fall risk factors in people with rheumatoid arthritis. Ann Rheum Dis. 2009;68:1795-6. doi: 10.1136/ard.2009.109009</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Kanis JA, Johansson H, Oden A, et al. A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res. 2004;19:893-9. doi: 10.1359/JBMR.040134</mixed-citation><mixed-citation xml:lang="en">Kanis JA, Johansson H, Oden A, et al. A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res. 2004;19:893-9. doi: 10.1359/JBMR.040134</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Kanis JA, Johansson H, Oden A, McCloskey EV. Guidance for the adjustment of FRAX according to the dose of glucocorticoids. Osteoporos Int. 2011;22:809-16. doi: 10.1007/s00198-010-1524-7</mixed-citation><mixed-citation xml:lang="en">Kanis JA, Johansson H, Oden A, McCloskey EV. Guidance for the adjustment of FRAX according to the dose of glucocorticoids. Osteoporos Int. 2011;22:809-16. doi: 10.1007/s00198-010-1524-7</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Buckley L, Guyatt G, Fink HA, et al. 2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. Arthritis Rheum. 2017;69(8):1521-37. doi: 10.1002/art.40137</mixed-citation><mixed-citation xml:lang="en">Buckley L, Guyatt G, Fink HA, et al. 2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. Arthritis Rheum. 2017;69(8):1521-37. doi: 10.1002/art.40137</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Насонов ЕЛ, редактор. Российские клинические рекоменда- ции. Ревматология. Москва: ГЭОТАР-Медиа; 2017. 464 с. [Nasonov EL, editor. Rossijskie klinicheskie rekomendacii. Revmatologiya. [Russian clinical guidelines. Rheumatology]. Moscow: GEOTAR-Media; 2017. 464 p. (In Russ.)].</mixed-citation><mixed-citation xml:lang="en">Насонов ЕЛ, редактор. Российские клинические рекоменда- ции. Ревматология. Москва: ГЭОТАР-Медиа; 2017. 464 с. [Nasonov EL, editor. Rossijskie klinicheskie rekomendacii. Revmatologiya. [Russian clinical guidelines. Rheumatology]. Moscow: GEOTAR-Media; 2017. 464 p. (In Russ.)].</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Kanis JA, Harvey NC, Cooper C, et al. Advisory Board of the National Osteoporosis Guideline Group. A systematic review of intervention thresholds based on FRAX: A report prepared for the National Osteoporosis Guideline Group and the International Osteoporosis Foundation. Arch Osteoporos. 2016;11(1):25. doi: 10.1007/s11657-016-0278-z</mixed-citation><mixed-citation xml:lang="en">Kanis JA, Harvey NC, Cooper C, et al. Advisory Board of the National Osteoporosis Guideline Group. A systematic review of intervention thresholds based on FRAX: A report prepared for the National Osteoporosis Guideline Group and the International Osteoporosis Foundation. Arch Osteoporos. 2016;11(1):25. doi: 10.1007/s11657-016-0278-z</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">The National Osteoporosis Foundation (NOF) Clinician's Guide to prevention and treatment of osteoporosis 2014. Osteoporos Int. 2014;25(10):2359-81. doi: 10.1007/s00198-014-2794-2</mixed-citation><mixed-citation xml:lang="en">The National Osteoporosis Foundation (NOF) Clinician's Guide to prevention and treatment of osteoporosis 2014. Osteoporos Int. 2014;25(10):2359-81. doi: 10.1007/s00198-014-2794-2</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Никитинская ОА, Торопцова НВ, Демин НВ. Факторы риска и минеральная плотность кости в прогнозировании риска перелома у женщин в постменопаузе. Современная ревматология. 2016;10(3):23-8 [Nikitinskaya OA, Toroptsova NV, Demin NV. Risk factors and bone mineral density in predicting the risk of fracture in postmenopausal women. Sovremennaya revmatologiya. 2016;10(3):23-8 (In Russ.)]. doi: 10.14412/1996-7012-2016-3-23-28</mixed-citation><mixed-citation xml:lang="en">Никитинская ОА, Торопцова НВ, Демин НВ. Факторы риска и минеральная плотность кости в прогнозировании риска перелома у женщин в постменопаузе. Современная ревматология. 2016;10(3):23-8 [Nikitinskaya OA, Toroptsova NV, Demin NV. Risk factors and bone mineral density in predicting the risk of fracture in postmenopausal women. Sovremennaya revmatologiya. 2016;10(3):23-8 (In Russ.)]. doi: 10.14412/1996-7012-2016-3-23-28</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Silverman SL, Calderon AD. The utility and limitations of FRAX: a US perspective. Curr Osteoporos Rep. 2010;8:192-7.</mixed-citation><mixed-citation xml:lang="en">Silverman SL, Calderon AD. The utility and limitations of FRAX: a US perspective. Curr Osteoporos Rep. 2010;8:192-7.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Kanis J, McCloskey E, Johansson H, et al. FRAX with and without bone mineral density. Calcif Tissue Int. 2012; 90:1-13.</mixed-citation><mixed-citation xml:lang="en">Kanis J, McCloskey E, Johansson H, et al. FRAX with and without bone mineral density. Calcif Tissue Int. 2012; 90:1-13.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Hamdy RC, Kiebzak GM. Variance in 10-year fracture risk calculated with and without T-scores in select subgroups of normal and osteoporotic patients. J Clin Densitom. 2009;12:158-61.</mixed-citation><mixed-citation xml:lang="en">Hamdy RC, Kiebzak GM. Variance in 10-year fracture risk calculated with and without T-scores in select subgroups of normal and osteoporotic patients. J Clin Densitom. 2009;12:158-61.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Olmez Sarikaya N, Kapar Yavasi S, Tan G, et al. Agreement between FRAX scores calculated with and without bone mineral density in women with osteopenia in Turkey. Clin Rheumatol. 2014;33:1785-9. doi: 10.1007/s10067-014-2491-8</mixed-citation><mixed-citation xml:lang="en">Olmez Sarikaya N, Kapar Yavasi S, Tan G, et al. Agreement between FRAX scores calculated with and without bone mineral density in women with osteopenia in Turkey. Clin Rheumatol. 2014;33:1785-9. doi: 10.1007/s10067-014-2491-8</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Kim JW, Koh J-M, Park JH, Chang JS Validation of FRAX without BMD: an age-related analysis of the Fifth Korean National Health and Nutrition Examination Survey (KNHANES V-1, 2010). Bone. 2015;7(5):27-31. doi: 10.1016/j.bone.2015.02.013</mixed-citation><mixed-citation xml:lang="en">Kim JW, Koh J-M, Park JH, Chang JS Validation of FRAX without BMD: an age-related analysis of the Fifth Korean National Health and Nutrition Examination Survey (KNHANES V-1, 2010). Bone. 2015;7(5):27-31. doi: 10.1016/j.bone.2015.02.013</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Bastos-Silva Y, Aguiar LB, Pinto-Neto AM, et al. Correlation between osteoporotic fracture risk in Brazilian postmenopausal women calculated using the FRAX with and without the inclusion of bone densitometry data. Arch Osteoporos. 2016;11:16. doi: 10.1007/s11657-015-0255-y</mixed-citation><mixed-citation xml:lang="en">Bastos-Silva Y, Aguiar LB, Pinto-Neto AM, et al. Correlation between osteoporotic fracture risk in Brazilian postmenopausal women calculated using the FRAX with and without the inclusion of bone densitometry data. Arch Osteoporos. 2016;11:16. doi: 10.1007/s11657-015-0255-y</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Elde KD, Madsen OR. FRAX 10-yr Fracture Risk in Rheumatoid Arthritis-Assessments With and Without Bone Mineral Density May Lead to Very Different Results in the Individual Patient. J Clin Densitom. 2018 Oct 31. doi: 10.1016/j.jocd.2018.10.007</mixed-citation><mixed-citation xml:lang="en">Elde KD, Madsen OR. FRAX 10-yr Fracture Risk in Rheumatoid Arthritis-Assessments With and Without Bone Mineral Density May Lead to Very Different Results in the Individual Patient. J Clin Densitom. 2018 Oct 31. doi: 10.1016/j.jocd.2018.10.007</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Egsmose EL, Birkvig M, Buhl T, Madsen OR. FRAX fracture risk in women with a recent fracture of the distal forearm: agreement between assessments with and without bone mineral density and impact of measurement side in the individual patient. Clin Rheumatol. 2015;34:1265-72. doi: 10.1007/s10067-014-2640-0</mixed-citation><mixed-citation xml:lang="en">Egsmose EL, Birkvig M, Buhl T, Madsen OR. FRAX fracture risk in women with a recent fracture of the distal forearm: agreement between assessments with and without bone mineral density and impact of measurement side in the individual patient. Clin Rheumatol. 2015;34:1265-72. doi: 10.1007/s10067-014-2640-0</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Leslie WD, Morin S, Lix LM, et al. Fracture risk assessment without bone density measurement in routine clinical practice. Osteoporos Int. 2012;23(1):75-85. doi: 10.1007/s00198-011-1747-2</mixed-citation><mixed-citation xml:lang="en">Leslie WD, Morin S, Lix LM, et al. Fracture risk assessment without bone density measurement in routine clinical practice. Osteoporos Int. 2012;23(1):75-85. doi: 10.1007/s00198-011-1747-2</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Choi ST, Kwon SR, Jung JY, et al. Prevalence and Fracture Risk of Osteoporosis in Patients with Rheumatoid Arthritis: A Multicenter Comparative Study of the FRAX and WHO Criteria. J Clin Med. 2018;7(12):507. doi: 10.3390/jcm7120507</mixed-citation><mixed-citation xml:lang="en">Choi ST, Kwon SR, Jung JY, et al. Prevalence and Fracture Risk of Osteoporosis in Patients with Rheumatoid Arthritis: A Multicenter Comparative Study of the FRAX and WHO Criteria. J Clin Med. 2018;7(12):507. doi: 10.3390/jcm7120507</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Meng J, Li Y, Yuan X, Lu Y. Evaluating osteoporotic fracture risk with the Fracture Risk Assessment Tool in Chinese patients with rheumatoid arthritis. Medicine (Baltimore). 2017;96(18):6677. doi: 10.1097/MD.0000000000006677</mixed-citation><mixed-citation xml:lang="en">Meng J, Li Y, Yuan X, Lu Y. Evaluating osteoporotic fracture risk with the Fracture Risk Assessment Tool in Chinese patients with rheumatoid arthritis. Medicine (Baltimore). 2017;96(18):6677. doi: 10.1097/MD.0000000000006677</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Мельниченко ГА, Белая ЖЕ, Рожинская ЛЯ и др. Федеральные клинические рекомендации по диагностике, лечению и профилактике остеопороза. Проблемы эндокринологии. 2017;63(6):392-426 [Melnichenko GA, Belaya ZE, Rozhinskaya LYa, et al. Russian clinical guidelines on the diagnostics, treatment, and prevention of osteoporosis. Problemy Endokrinologii. 2017;63(6):392-426 (In Russ.)]. doi: 10.14341/probl2017636392-426</mixed-citation><mixed-citation xml:lang="en">Мельниченко ГА, Белая ЖЕ, Рожинская ЛЯ и др. Федеральные клинические рекомендации по диагностике, лечению и профилактике остеопороза. Проблемы эндокринологии. 2017;63(6):392-426 [Melnichenko GA, Belaya ZE, Rozhinskaya LYa, et al. Russian clinical guidelines on the diagnostics, treatment, and prevention of osteoporosis. Problemy Endokrinologii. 2017;63(6):392-426 (In Russ.)]. doi: 10.14341/probl2017636392-426</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Баранова ИА, Торопцова НВ, Лесняк ОМ. Основные положения клинических рекомендаций «Диагностика, профилактика и лечение глюкокортикоидного остеопороза у мужчин и женщин 18 лет и старше». Остеопороз и остеопатии. 2014;(3):34-7 [Baranova IA, Toropcova NV, Lesnyak OM. The main provisions of the clinical guidelines «Diagnosis, prevention and treatment of glucocorticoid osteoporosis in men and women 18 years and older». Osteoporoz i osteopatii. 2014;(3):34-7 (In Russ.)].</mixed-citation><mixed-citation xml:lang="en">Баранова ИА, Торопцова НВ, Лесняк ОМ. Основные положения клинических рекомендаций «Диагностика, профилактика и лечение глюкокортикоидного остеопороза у мужчин и женщин 18 лет и старше». Остеопороз и остеопатии. 2014;(3):34-7 [Baranova IA, Toropcova NV, Lesnyak OM. The main provisions of the clinical guidelines «Diagnosis, prevention and treatment of glucocorticoid osteoporosis in men and women 18 years and older». Osteoporoz i osteopatii. 2014;(3):34-7 (In Russ.)].</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
